Section of Otolaryngology, Department of Medicine, Fukuoka Dental College, Fukuoka, Japan;
Nishi Otolaryngology Clinic, Fukuoka, Japan.
In Vivo. 2022 Jan-Feb;36(1):371-374. doi: 10.21873/invivo.12712.
The epipharynx, with its high expression of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) entry factors angiotensin-converting enzyme 2 (ACE2) and transmembrane protease, serine 2 (TMPRSS2), is a primary target for SARS-CoV-2 replication in the early stage of Coronavirus Disease 19 (COVID-19). Epipharyngeal abrasive therapy (EAT) is a treatment for epipharyngitis in Japan which involves applying zinc chloride to the epipharyngeal mucosa. In this study, we evaluated the expression patterns of ACE2 and TMPRSS2 in tissue samples from patients before and after EAT.
The study subjects were seven patients that had not been treated with EAT and 11 patients that had. For immunohistochemical assessment of the epipharyngeal mucosa, the staining intensity of ACE2 and TMPRSS2 was described as an immunohistochemical score (IHC score).
The IHC scores for ACE2 and TEMPRSS2 in the EAT-treated group were 3.40-fold and 1.81-fold lower, respectively, than those in the non-treated group (p=0.0208 and p=0.0244, respectively).
EAT down-regulates the expression of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Thus, EAT has potential as a novel COVID-19 preventative method.
咽上部组织具有较高的 SARS-CoV-2 进入因子血管紧张素转换酶 2(ACE2)和跨膜丝氨酸蛋白酶 2(TMPRSS2)的表达水平,是 2019 年冠状病毒病(COVID-19)早期 SARS-CoV-2 复制的主要靶标。咽上部摩擦疗法(EAT)是日本治疗咽上部炎的一种方法,即用氯化锌涂于咽上部黏膜。本研究评估了 EAT 治疗前后患者咽上部组织样本中 ACE2 和 TMPRSS2 的表达模式。
研究对象为 7 例未经 EAT 治疗的患者和 11 例 EAT 治疗的患者。对咽上部黏膜进行免疫组织化学评估,ACE2 和 TMPRSS2 的染色强度用免疫组化评分(IHC 评分)来描述。
EAT 治疗组的 ACE2 和 TEMPRSS2 的 IHC 评分分别比未治疗组低 3.40 倍和 1.81 倍(p=0.0208 和 p=0.0244)。
EAT 下调了 SARS-CoV-2 进入因子 ACE2 和 TMPRSS2 的表达。因此,EAT 作为一种新型 COVID-19 预防方法具有潜力。